These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 32621557

  • 21. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.
    Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA, Poulter NR, Pratley RE, Thomsen AB, Buse JB, LEADER Trial Investigators.
    J Am Coll Cardiol; 2020 Mar 17; 75(10):1128-1141. PubMed ID: 32164886
    [Abstract] [Full Text] [Related]

  • 22. Glycated hemoglobin variability and the risk of cardiovascular events in patients with prediabetes and type 2 diabetes mellitus: A post-hoc analysis of a prospective and multicenter study.
    Manosroi W, Phimphilai M, Waisayanand N, Buranapin S, Deerochanawong C, Gunaparn S, Phrommintikul A, Wongcharoen W, CORE-Thailand investigators.
    J Diabetes Investig; 2023 Dec 17; 14(12):1391-1400. PubMed ID: 37610280
    [Abstract] [Full Text] [Related]

  • 23. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
    Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, Liu Y, Gourlie NM, Cannon CP, EXAMINE Investigators.
    Diabetes Obes Metab; 2017 May 17; 19(5):664-671. PubMed ID: 28058763
    [Abstract] [Full Text] [Related]

  • 24. International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
    Bhatt AS, Luo N, Solomon N, Pagidipati NJ, Ambrosio G, Green JB, McGuire DK, Standl E, Cornel JH, Halvorsen S, Lopes RD, White HD, Holman RR, Peterson ED, Mentz RJ, TECOS Study Group.
    Am Heart J; 2019 Dec 17; 218():57-65. PubMed ID: 31707329
    [Abstract] [Full Text] [Related]

  • 25. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
    Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, Lopes RD, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Care; 2016 Dec 17; 39(12):2304-2310. PubMed ID: 27742728
    [Abstract] [Full Text] [Related]

  • 26. Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Reed SD, Li Y, Leal J, Radican L, Adler AI, Alfredsson J, Buse JB, Green JB, Kaufman KD, Riefflin A, Van de Werf F, Peterson ED, Gray AM, Holman RR, TECOS Study Group.
    Diabetes Obes Metab; 2018 Jul 17; 20(7):1732-1739. PubMed ID: 29573215
    [Abstract] [Full Text] [Related]

  • 27. Glycated Hemoglobin Variability Is Associated With Adverse Outcomes in Patients With Heart Failure Irrespective of Diabetic Status.
    Xu X, Ren QW, Chandramouli C, Ng MY, Tsang CT, Tse YK, Li XL, Liu MY, Wu MZ, Huang JY, Cheang IF, Yang JF, Wang F, Lam CSP, Yiu KH.
    J Am Heart Assoc; 2024 May 07; 13(9):e034109. PubMed ID: 38686852
    [Abstract] [Full Text] [Related]

  • 28. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
    Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riddle MC, Rydén L, Xavier D, Atisso CM, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona-Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw J, Sheu WH, Temelkova-Kurktschiev T, REWIND Trial Investigators.
    Diabetes Obes Metab; 2018 Jan 07; 20(1):42-49. PubMed ID: 28573765
    [Abstract] [Full Text] [Related]

  • 29. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Scirica BM, Im K, Murphy SA, Kuder JF, Rodriguez DA, Lopes RD, Green JB, Ruff CT, Sabatine MS.
    Clin Cardiol; 2022 Jul 07; 45(7):794-801. PubMed ID: 35715946
    [Abstract] [Full Text] [Related]

  • 30. Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c.
    Cavender MA, Scirica BM, Raz I, Steg PG, McGuire DK, Leiter LA, Hirshberg B, Davidson J, Cahn A, Mosenzon O, Im K, Braunwald E, Bhatt DL.
    Am J Med; 2016 Mar 07; 129(3):340.e1-8. PubMed ID: 26524706
    [Abstract] [Full Text] [Related]

  • 31. Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Davis TME, Mulder H, Lokhnygina Y, Aschner P, Chuang LM, Raffo Grado CA, Standl E, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Obes Metab; 2018 Jun 07; 20(6):1427-1434. PubMed ID: 29405540
    [Abstract] [Full Text] [Related]

  • 32. Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial.
    Segar MW, Patel KV, Vaduganathan M, Caughey MC, Butler J, Fonarow GC, Grodin JL, McGuire DK, Pandey A.
    Diabetes Care; 2020 Aug 07; 43(8):1920-1928. PubMed ID: 32540922
    [Abstract] [Full Text] [Related]

  • 33. [TECOS: confirmation of the cardiovascular safety of sitaliptin].
    Scheen AJ, Paquot N.
    Rev Med Liege; 2015 Oct 07; 70(10):511-6. PubMed ID: 26727841
    [Abstract] [Full Text] [Related]

  • 34. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
    Branch KRH, Dagenais GR, Avezum A, Basile J, Conget I, Cushman WC, Jansky P, Lakshmanan M, Lanas F, Leiter LA, Pais P, Pogosova N, Raubenheimer PJ, Ryden L, Shaw JE, Sheu WHH, Temelkova-Kurktschiev T, Bethel MA, Gerstein HC, Chinthanie R, Probstfield JL.
    Eur J Heart Fail; 2022 Oct 07; 24(10):1805-1812. PubMed ID: 36073143
    [Abstract] [Full Text] [Related]

  • 35. Hemoglobin A1c predicts heart failure hospitalization independent of baseline cardiac function or B-type natriuretic peptide level.
    Kishimoto I, Makino H, Ohata Y, Tamanaha T, Tochiya M, Kada A, Ishihara M, Anzai T, Shimizu W, Yasuda S, Ogawa H.
    Diabetes Res Clin Pract; 2014 May 07; 104(2):257-65. PubMed ID: 24629410
    [Abstract] [Full Text] [Related]

  • 36. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, Iqbal N, Öhman P, Lopes RD, Reicher B, Holman RR, Hernandez AF, Mentz RJ.
    Circulation; 2019 Nov 12; 140(20):1613-1622. PubMed ID: 31542942
    [Abstract] [Full Text] [Related]

  • 37. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
    Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Najafzadeh M, Koeneman L, Farsani SF, Déruaz-Luyet A, Paik JM, Patorno E.
    JAMA Netw Open; 2022 Oct 03; 5(10):e2237606. PubMed ID: 36264574
    [Abstract] [Full Text] [Related]

  • 38. Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
    De Ferrari GM, Stevens SR, Ambrosio G, Leonardi S, Armstrong PW, Green JB, Wamil M, Holman RR, Peterson ED, TECOS Study Group.
    Am Heart J; 2020 Feb 03; 220():82-88. PubMed ID: 31790905
    [Abstract] [Full Text] [Related]

  • 39. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
    Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators.
    Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217
    [Abstract] [Full Text] [Related]

  • 40. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC, Botros FT, Atisso CM, Sager PT.
    Cardiovasc Diabetol; 2016 Feb 24; 15():38. PubMed ID: 26912057
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.